The role of 14-3-3 η as a biomarker in rheumatoid arthritis

  title={The role of 14-3-3 $\eta$ as a biomarker in rheumatoid arthritis},
  author={dima abdelhafiz and S. Kilborn and Marwan Bukhari},
  journal={Rheumatology and Immunology Research},
  pages={87 - 90}
Abstract Rheumatoid arthritis (RA) is a chronic multisystem inflammatory disorder with significant morbidity and mortality. Making an early diagnosis and providing appropriate treatment decisions based on clinical and other parameter results in good disease control. Biomarkers, such as C reactive protein (CRP), anti-cyclic citrullinated peptides (anti-CCP), and erythrocyte sedimentation rate (ESR), have been traditionally used. Recently novel biomarkers are described. This article reviews the… 

Tables from this paper



14-3-3η protein: a promising biomarker for rheumatoid arthritis.

The emerging knowledge regarding the roles 14-3-3η plays in RA and its clinical implications as diagnostic, prognostic and therapeutic response surrogate as well as potential drug target for RA are summarized.

Evaluation of a new biomarker 14-3-3 Eta protein in diagnosis of rheumatoid arthritis

It is demonstrated that serum levels of 14-3-3 η were significantly higher in cases compared to controls and appears to be a useful and highly specific marker in RA.

14-3-3η Protein in Rheumatoid Arthritis: Promising Diagnostic Marker and Independent Risk Factor for Osteoporosis.

Serum 14-3-3η detection by itself or combined with other serum indices was helpful in differentiating patients with RA and was a promising biomarker for disease monitoring in RA.

SAT0211 14-3-3 ETA Protein: A Novel Biomarker for the Diagnosis of Rheumatoid Arthritis

This study investigated if serum 14-3-3 η enhanced the detection of RA over RF or anti-CCP in RA patients to prevent underdiagnosis in this subset of patients and found the utility of this protein as a diagnostic test to be poor.

14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage

It is shown that 14-3-3η complemented markers such as CRP, RF and ACPA in informing RA radiographic status and/or progression and its expression is higher in patients with radiographic damage and RA progression.

14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis

14-3-3η autoantibodies, alone and in combination with the 14-2-2η protein, RF, and/or ACPA identified most patients with early rheumatoid arthritis.

Serum 14-3-3η Could Improve the Diagnostic Rate of Rheumatoid Arthritis and Correlates to Disease Activity.

14-3-3η protein is a novel marker that can apparently enhance the detection rate of patients with RA and correlates to some degree with disease activity.

Comparison of Serum Levels of 14-3-3 ETA Proteins between Rheumatoid Arthritis, Osteoarthritis and Normal Controls.

14-3-3 ETA is a novel marker for RA that should be used in conjunction with RF and ACPA for diagnosis of the disease.

Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis

Levels of 14-3-3η protein predict poorer clinical and radiographic outcomes in EPA, both at baseline and after initiation of treatment, even in SDAI remitters.

Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

Pretreatment 14-3-3η levels informed 1-year DAS28-ESR remission in the TCZ-treated group, in contrast to the ADA, MTX, or TOF groups, while no differences in pret treatment 14- 3- 3η expression based on clinical response were evaluated.